Formation Bio valuation, funding and investors
Formation Bio works in AI-Driven drug development solutions, based in New York, United States. Founded in 2013, it has about 198 employees.
VALUATION · TODAY
$6.00B −34% after Series D
Range $1.47B – $8.52B · Grade CTODAY
+12 MO
$2.00B
$4.00B
$6.00B
$8.00B
$10.00B
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Series C $156M
Series D $372M
ValuationBefore first round12-month outlook: where it points, how wide it fansHover the past: the outlook shows what was predicted then
HEADCOUNT · TODAY198 employees
+5%6m growth
+9%1y growth
+16%2y growth
100
200
300
Data from Mar 2024
Predicted in 1 yr $3.99B −34% vs today
Predicted next raise $660M if a round comes
Winding-down probability 0%
- Last round
- Series D · $372M · Jun 2024
- Valuation at last round
- $4.47B · implied
- Headcount
- 198 · flat
- Grade
- C
- Founded
- 2013
Formation Bio valuation today
VCMC values Formation Bio at $6.0B today, with a range of $1.5B to $8.5B and a grade of C. The valuation starts from its last funding round, a Series D round in Jun 2024.
Valuation by date (168 rows)
Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.
| Date | Valuation | Range | Predicted in 1 yr | Phase | Headcount | Trend | Grade | Winding-down probability |
|---|---|---|---|---|---|---|---|---|
| 1 Jan 2013 | $4.78M | $1.74M – $13.1M | $5.01M (+5%) | before first round | – | unknown | D | 0% |
| 1 Feb 2013 | $4.80M | $1.75M – $13.2M | $5.03M (+5%) | before first round | – | unknown | D | 0% |
| 1 Mar 2013 | $4.82M | $1.75M – $13.2M | $5.05M (+5%) | before first round | – | unknown | D | 0% |
| 1 Apr 2013 | $4.84M | $1.76M – $13.3M | $5.07M (+5%) | before first round | – | unknown | D | 0% |
| 1 May 2013 | $4.86M | $1.77M – $13.3M | $5.09M (+5%) | before first round | – | unknown | D | 0% |
| 1 Jun 2013 | $4.88M | $1.78M – $13.4M | $5.11M (+5%) | before first round | – | unknown | D | 0% |
| 1 Jul 2013 | $4.90M | $1.78M – $13.5M | $5.13M (+5%) | before first round | – | unknown | D | 0% |
| 1 Aug 2013 | $4.92M | $1.79M – $13.5M | $5.15M (+5%) | before first round | – | unknown | D | 0% |
| 1 Sep 2013 | $4.94M | $1.80M – $13.6M | $5.17M (+5%) | before first round | – | unknown | D | 0% |
| 1 Oct 2013 | $4.95M | $1.80M – $13.6M | $5.19M (+5%) | before first round | – | unknown | D | 0% |
| 1 Nov 2013 | $4.97M | $1.81M – $13.7M | $5.21M (+5%) | before first round | – | unknown | D | 0% |
| 1 Dec 2013 | $4.99M | $1.82M – $13.7M | $5.23M (+5%) | before first round | – | unknown | D | 0% |
| 1 Jan 2014 | $5.01M | $1.83M – $13.8M | $5.25M (+5%) | before first round | – | unknown | D | 0% |
| 1 Feb 2014 | $5.03M | $1.83M – $13.8M | $5.28M (+5%) | before first round | – | unknown | D | 0% |
| 1 Mar 2014 | $5.05M | $1.84M – $13.9M | $5.29M (+5%) | before first round | – | unknown | D | 0% |
| 1 Apr 2014 | $5.07M | $1.85M – $13.9M | $5.32M (+5%) | before first round | – | unknown | D | 0% |
| 1 May 2014 | $5.09M | $1.85M – $14.0M | $5.34M (+5%) | before first round | – | unknown | D | 0% |
| 1 Jun 2014 | $5.11M | $1.86M – $14.0M | $5.36M (+5%) | before first round | – | unknown | D | 0% |
| 1 Jul 2014 | $5.13M | $1.87M – $14.1M | $5.38M (+5%) | before first round | – | unknown | D | 0% |
| 1 Aug 2014 | $5.15M | $1.88M – $14.2M | $5.40M (+5%) | before first round | – | unknown | D | 0% |
| 1 Sep 2014 | $5.17M | $1.88M – $14.2M | $5.42M (+5%) | before first round | – | unknown | D | 0% |
| 1 Oct 2014 | $5.19M | $1.89M – $14.3M | $5.44M (+5%) | before first round | – | unknown | D | 0% |
| 1 Nov 2014 | $5.21M | $1.90M – $14.3M | $5.46M (+5%) | before first round | – | unknown | D | 0% |
| 1 Dec 2014 | $5.23M | $1.91M – $14.4M | $5.48M (+5%) | before first round | – | unknown | D | 0% |
| 1 Jan 2015 | $5.25M | $1.91M – $14.4M | $5.51M (+5%) | before first round | – | unknown | D | 0% |
| 1 Feb 2015 | $5.28M | $1.92M – $14.5M | $5.53M (+5%) | before first round | – | unknown | D | 0% |
| 1 Mar 2015 | $5.29M | $1.93M – $14.5M | $5.55M (+5%) | before first round | – | unknown | D | 0% |
| 1 Apr 2015 | $5.32M | $1.93M – $14.6M | $5.57M (+5%) | before first round | – | unknown | D | 0% |
| 1 May 2015 | $5.34M | $1.94M – $14.7M | $5.59M (+5%) | before first round | – | unknown | D | 0% |
| 1 Jun 2015 | $5.36M | $1.95M – $14.7M | $5.61M (+5%) | before first round | – | unknown | D | 0% |
| 1 Jul 2015 | $5.38M | $1.96M – $14.8M | $5.64M (+5%) | before first round | – | unknown | D | 0% |
| 1 Aug 2015 | $5.40M | $1.97M – $14.8M | $5.78M (+7%) | before first round | – | unknown | D | 0% |
| 1 Sep 2015 | $5.42M | $1.97M – $14.9M | $5.94M (+10%) | before first round | – | unknown | D | 0% |
| 1 Oct 2015 | $5.44M | $1.98M – $14.9M | $6.09M (+12%) | before first round | – | unknown | D | 0% |
| 1 Nov 2015 | $5.46M | $1.99M – $15.0M | $6.26M (+15%) | before first round | – | unknown | D | 0% |
| 1 Dec 2015 | $5.48M | $2.00M – $15.1M | $6.42M (+17%) | before first round | – | unknown | D | 0% |
| 1 Jan 2016 | $5.51M | $2.00M – $15.1M | $6.60M (+20%) | before first round | – | unknown | D | 0% |
| 1 Feb 2016 | $5.53M | $2.01M – $15.2M | $6.78M (+23%) | before first round | – | unknown | D | 0% |
| 1 Mar 2016 | $5.55M | $2.02M – $15.2M | $6.95M (+25%) | before first round | – | unknown | D | 0% |
| 1 Apr 2016 | $5.57M | $2.03M – $15.3M | $7.14M (+28%) | before first round | – | unknown | D | 0% |
| 1 May 2016 | $5.59M | $2.04M – $15.4M | $7.33M (+31%) | before first round | – | unknown | D | 0% |
| 1 Jun 2016 | $5.61M | $2.04M – $15.4M | $7.53M (+34%) | before first round | – | unknown | D | 0% |
| 1 Jul 2016 | $5.64M | $2.05M – $15.5M | $7.72M (+37%) | before first round | – | unknown | D | 0% |
| 1 Aug 2016 | $5.79M | $2.11M – $15.9M | $7.93M (+37%) | before first round | – | unknown | D | 0% |
| 1 Sep 2016 | $5.94M | $2.16M – $16.3M | $8.15M (+37%) | before first round | – | unknown | D | 0% |
| 1 Oct 2016 | $6.10M | $2.22M – $16.8M | $8.36M (+37%) | before first round | – | unknown | D | 0% |
| 1 Nov 2016 | $6.26M | $2.28M – $17.2M | $8.59M (+37%) | before first round | – | unknown | D | 0% |
| 1 Dec 2016 | $6.43M | $2.34M – $17.7M | $8.81M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jan 2017 | $6.60M | $2.40M – $18.1M | $9.05M (+37%) | before first round | – | unknown | D | 0% |
| 1 Feb 2017 | $6.78M | $2.47M – $18.6M | $9.29M (+37%) | before first round | – | unknown | D | 0% |
| 1 Mar 2017 | $6.94M | $2.53M – $19.1M | $9.52M (+37%) | before first round | – | unknown | D | 0% |
| 1 Apr 2017 | $7.13M | $2.60M – $19.6M | $9.78M (+37%) | before first round | – | unknown | D | 0% |
| 1 May 2017 | $7.32M | $2.67M – $20.1M | $10.0M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jun 2017 | $7.52M | $2.74M – $20.7M | $10.3M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jul 2017 | $7.72M | $2.81M – $21.2M | $10.6M (+37%) | before first round | – | unknown | D | 0% |
| 1 Aug 2017 | $7.93M | $2.89M – $21.8M | $10.9M (+37%) | before first round | – | unknown | D | 0% |
| 1 Sep 2017 | $8.14M | $2.96M – $22.4M | $11.2M (+37%) | before first round | – | unknown | D | 0% |
| 1 Oct 2017 | $8.36M | $3.04M – $23.0M | $11.5M (+37%) | before first round | – | unknown | D | 0% |
| 1 Nov 2017 | $8.58M | $3.12M – $23.6M | $11.8M (+37%) | before first round | – | unknown | D | 0% |
| 1 Dec 2017 | $8.81M | $3.21M – $24.2M | $12.1M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jan 2018 | $9.05M | $3.29M – $24.9M | $12.4M (+37%) | before first round | – | unknown | D | 0% |
| 1 Feb 2018 | $9.29M | $3.38M – $25.5M | $12.7M (+37%) | before first round | – | unknown | D | 0% |
| 1 Mar 2018 | $9.52M | $3.47M – $26.2M | $13.1M (+37%) | before first round | – | unknown | D | 0% |
| 1 Apr 2018 | $9.78M | $3.56M – $26.9M | $13.4M (+37%) | before first round | – | unknown | D | 0% |
| 1 May 2018 | $10.0M | $3.65M – $27.6M | $13.8M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jun 2018 | $10.3M | $3.75M – $28.3M | $14.1M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jul 2018 | $10.6M | $3.85M – $29.1M | $14.5M (+37%) | before first round | – | unknown | D | 0% |
| 1 Aug 2018 | $10.9M | $3.96M – $29.9M | $14.7M (+35%) | before first round | – | unknown | D | 0% |
| 1 Sep 2018 | $11.2M | $4.06M – $30.7M | $14.8M (+32%) | before first round | – | unknown | D | 0% |
| 1 Oct 2018 | $11.5M | $4.17M – $31.5M | $14.9M (+30%) | before first round | – | unknown | D | 0% |
| 1 Nov 2018 | $11.8M | $4.28M – $32.3M | $15.1M (+28%) | before first round | – | unknown | D | 0% |
| 1 Dec 2018 | $12.1M | $4.40M – $33.2M | $15.2M (+26%) | before first round | – | unknown | D | 0% |
| 1 Jan 2019 | $12.4M | $4.52M – $34.1M | $15.3M (+24%) | before first round | – | unknown | D | 0% |
| 1 Feb 2019 | $12.7M | $4.64M – $35.0M | $15.5M (+21%) | before first round | – | unknown | D | 0% |
| 1 Mar 2019 | $13.1M | $4.75M – $35.9M | $15.6M (+19%) | before first round | – | unknown | D | 0% |
| 1 Apr 2019 | $13.4M | $4.88M – $36.8M | $15.7M (+17%) | before first round | – | unknown | D | 0% |
| 1 May 2019 | $13.8M | $5.01M – $37.8M | $15.9M (+15%) | before first round | – | unknown | D | 0% |
| 1 Jun 2019 | $14.1M | $5.15M – $38.8M | $16.0M (+13%) | before first round | – | unknown | D | 0% |
| 1 Jul 2019 | $14.5M | $5.28M – $39.8M | $16.2M (+11%) | before first round | – | unknown | D | 0% |
| 1 Aug 2019 | $14.7M | $5.33M – $40.2M | $16.3M (+11%) | before first round | – | unknown | D | 0% |
| 1 Sep 2019 | $14.8M | $5.38M – $40.6M | $16.5M (+11%) | before first round | – | unknown | D | 0% |
| 1 Oct 2019 | $14.9M | $5.43M – $41.0M | $16.6M (+11%) | before first round | – | unknown | D | 0% |
| 1 Nov 2019 | $15.1M | $5.48M – $41.4M | $16.8M (+11%) | before first round | – | unknown | D | 0% |
| 1 Dec 2019 | $15.2M | $5.53M – $41.7M | $16.9M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jan 2020 | $15.3M | $5.58M – $42.1M | $17.1M (+11%) | before first round | – | unknown | D | 0% |
| 1 Feb 2020 | $15.5M | $5.63M – $42.5M | $17.2M (+11%) | before first round | – | unknown | D | 0% |
| 1 Mar 2020 | $15.6M | $5.68M – $42.9M | $17.4M (+11%) | before first round | – | unknown | D | 0% |
| 1 Apr 2020 | $15.7M | $5.73M – $43.3M | $17.5M (+11%) | before first round | – | unknown | D | 0% |
| 1 May 2020 | $15.9M | $5.78M – $43.6M | $17.7M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jun 2020 | $16.0M | $5.84M – $44.0M | $17.9M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jul 2020 | $16.2M | $5.89M – $44.4M | $18.0M (+11%) | before first round | – | unknown | D | 0% |
| 1 Aug 2020 | $16.3M | $5.94M – $44.8M | $18.2M (+11%) | before first round | – | unknown | D | 0% |
| 1 Sep 2020 | $16.5M | $6.00M – $45.2M | $18.3M (+11%) | before first round | – | unknown | D | 0% |
| 1 Oct 2020 | $16.6M | $6.05M – $45.6M | $18.5M (+11%) | before first round | – | unknown | D | 0% |
| 1 Nov 2020 | $16.8M | $6.11M – $46.1M | $18.7M (+11%) | before first round | – | unknown | D | 0% |
| 1 Dec 2020 | $16.9M | $6.16M – $46.5M | $18.8M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jan 2021 | $17.1M | $6.21M – $46.9M | $19.0M (+11%) | before first round | – | unknown | D | 0% |
| 1 Feb 2021 | $17.2M | $6.27M – $47.3M | $19.2M (+11%) | before first round | – | unknown | D | 0% |
| 1 Mar 2021 | $17.4M | $6.32M – $47.7M | $19.3M (+11%) | before first round | – | unknown | D | 0% |
| 1 Apr 2021 | $17.5M | $6.38M – $48.2M | $19.4M (+11%) | before first round | – | unknown | D | 0% |
| 1 May 2021 | $17.7M | $6.44M – $48.6M | $19.6M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jun 2021 | $17.8M | $6.50M – $49.0M | $19.7M (+10%) | before first round | – | unknown | D | 0% |
| 1 Jul 2021 | $18.0M | $6.56M – $49.5M | $19.9M (+10%) | before first round | – | unknown | D | 0% |
| 1 Aug 2021 | $18.2M | $6.62M – $49.9M | $20.0M (+10%) | before first round | – | unknown | D | 0% |
| 1 Sep 2021 | $18.3M | $6.68M – $50.4M | $20.2M (+10%) | before first round | – | unknown | D | 0% |
| 1 Oct 2021 | $1.4B | $932M – $2.8B | $1.8B (+30%) | after a round | – | unknown | B | 0% |
| 1 Nov 2021 | $1.5B | $932M – $2.8B | $1.8B (+27%) | after a round | – | unknown | B | 0% |
| 1 Dec 2021 | $1.5B | $932M – $2.8B | $1.8B (+24%) | after a round | – | unknown | B | 0% |
| 1 Jan 2022 | $1.5B | $932M – $2.8B | $1.8B (+22%) | after a round | – | unknown | B | 0% |
| 1 Feb 2022 | $1.6B | $932M – $2.8B | $1.8B (+19%) | after a round | – | unknown | B | 0% |
| 1 Mar 2022 | $1.6B | $932M – $2.8B | $1.8B (+17%) | after a round | – | unknown | B | 0% |
| 1 Apr 2022 | $1.6B | $932M – $2.8B | $1.8B (+14%) | after a round | – | unknown | B | 0% |
| 1 May 2022 | $1.7B | $932M – $2.8B | $1.8B (+12%) | after a round | – | unknown | B | 0% |
| 1 Jun 2022 | $1.7B | $932M – $2.8B | $1.8B (+9%) | after a round | – | unknown | B | 0% |
| 1 Jul 2022 | $1.7B | $932M – $2.8B | $1.8B (+7%) | after a round | – | unknown | B | 0% |
| 1 Aug 2022 | $1.8B | $932M – $2.8B | $1.8B (+4%) | after a round | – | unknown | B | 0% |
| 1 Sep 2022 | $1.8B | $932M – $2.8B | $1.8B (+2%) | after a round | – | unknown | B | 0% |
| 1 Oct 2022 | $1.8B | $931M – $2.8B | $1.8B (0%) | after a round | – | unknown | B | 0% |
| 1 Nov 2022 | $1.8B | $889M – $2.8B | $1.8B (0%) | after a round | – | unknown | B | 0% |
| 1 Dec 2022 | $1.8B | $850M – $2.8B | $1.8B (0%) | after a round | – | unknown | B | 0% |
| 1 Jan 2023 | $1.8B | $811M – $2.8B | $1.8B (0%) | after a round | – | unknown | C | 0% |
| 1 Feb 2023 | $1.8B | $774M – $2.8B | $1.8B (0%) | after a round | – | unknown | C | 0% |
| 1 Mar 2023 | $1.8B | $743M – $2.8B | $1.8B (0%) | after a round | – | unknown | C | 0% |
| 1 Apr 2023 | $1.8B | $709M – $2.8B | $1.8B (0%) | after a round | – | unknown | C | 0% |
| 1 May 2023 | $1.8B | $678M – $2.8B | $1.8B (0%) | after a round | – | unknown | C | 0% |
| 1 Jun 2023 | $1.8B | $647M – $2.8B | $1.8B (0%) | after a round | – | unknown | C | 0% |
| 1 Jul 2023 | $1.8B | $619M – $2.8B | $1.8B (0%) | after a round | – | unknown | C | 0% |
| 1 Aug 2023 | $1.8B | $591M – $2.8B | $1.8B (0%) | after a round | – | unknown | C | 0% |
| 1 Sep 2023 | $1.8B | $564M – $2.8B | $1.8B (0%) | after a round | – | unknown | C | 0% |
| 1 Oct 2023 | $1.8B | $511M – $2.8B | $1.8B (0%) | after a round | – | unknown | C | 0% |
| 1 Nov 2023 | $1.8B | $486M – $2.8B | $1.8B (0%) | after a round | – | unknown | C | 0% |
| 1 Dec 2023 | $1.8B | $462M – $2.8B | $1.8B (0%) | after a round | – | unknown | C | 0% |
| 1 Jan 2024 | $1.8B | $439M – $2.8B | $1.8B (0%) | after a round | – | unknown | C | 0% |
| 1 Feb 2024 | $1.8B | $417M – $2.8B | $1.8B (0%) | after a round | – | unknown | C | 0% |
| 1 Mar 2024 | $1.8B | $398M – $2.8B | $1.8B (0%) | after a round | 170 | unknown | C | 0% |
| 1 Apr 2024 | $1.8B | $378M – $2.8B | $1.8B (0%) | after a round | 170 | unknown | D | 0% |
| 1 May 2024 | $1.8B | $360M – $2.8B | $1.8B (0%) | after a round | 170 | unknown | D | 0% |
| 1 Jun 2024 | $1.8B | $342M – $2.8B | $1.8B (0%) | after a round | 170 | unknown | D | 0% |
| 27 Jun 2024 | $4.5B | $3.1B – $8.2B | $5.8B (+30%) | after a round | 170 | unknown | B | 0% |
| 1 Jul 2024 | $4.5B | $3.1B – $8.2B | $5.8B (+30%) | after a round | 170 | flat | B | 0% |
| 1 Aug 2024 | $4.6B | $3.1B – $8.2B | $5.8B (+27%) | after a round | 170 | flat | B | 0% |
| 1 Sep 2024 | $4.7B | $3.1B – $8.2B | $5.8B (+24%) | after a round | 170 | flat | B | 0% |
| 1 Oct 2024 | $4.8B | $3.1B – $8.2B | $5.8B (+21%) | after a round | 170 | flat | B | 0% |
| 1 Nov 2024 | $4.9B | $3.1B – $8.2B | $5.8B (+19%) | after a round | 170 | flat | B | 0% |
| 1 Dec 2024 | $5.0B | $3.1B – $8.2B | $5.8B (+16%) | after a round | 170 | flat | B | 0% |
| 1 Jan 2025 | $5.1B | $3.1B – $8.2B | $5.8B (+13%) | after a round | 170 | flat | B | 0% |
| 1 Feb 2025 | $5.2B | $3.1B – $8.2B | $5.8B (+11%) | after a round | 170 | flat | B | 0% |
| 1 Mar 2025 | $5.3B | $3.1B – $8.2B | $5.8B (+9%) | after a round | 170 | flat | B | 0% |
| 1 Apr 2025 | $5.5B | $3.1B – $8.2B | $5.8B (+6%) | after a round | 170 | flat | B | 0% |
| 1 May 2025 | $5.6B | $3.1B – $8.2B | $5.8B (+4%) | after a round | 170 | flat | B | 0% |
| 1 Jun 2025 | $5.7B | $3.1B – $8.2B | $5.8B (+2%) | after a round | 170 | flat | B | 0% |
| 1 Jul 2025 | $5.9B | $3.2B – $8.4B | $5.9B (0%) | after a round | 181 | flat | B | 0% |
| 1 Aug 2025 | $5.9B | $3.0B – $8.3B | $5.9B (0%) | after a round | 179 | flat | B | 0% |
| 1 Sep 2025 | $5.9B | $2.9B – $8.3B | $5.9B (0%) | after a round | 179 | flat | B | 0% |
| 1 Oct 2025 | $5.9B | $2.8B – $8.4B | $5.9B (0%) | after a round | 181 | flat | B | 0% |
| 1 Nov 2025 | $5.9B | $2.6B – $8.4B | $5.9B (0%) | after a round | 181 | flat | B | 0% |
| 1 Dec 2025 | $5.9B | $2.5B – $8.4B | $5.9B (0%) | after a round | 181 | flat | B | 0% |
| 1 Jan 2026 | $5.9B | $3.0B – $8.4B | $5.9B (0%) | after a round | 189 | up | B | 0% |
| 1 Feb 2026 | $5.9B | $3.0B – $8.4B | $5.9B (0%) | after a round | 189 | up | B | 0% |
| 1 Mar 2026 | $5.9B | $2.9B – $8.4B | $5.9B (0%) | after a round | 189 | up | B | 0% |
| 1 Apr 2026 | $5.9B | $2.9B – $8.4B | $5.9B (0%) | after a round | 189 | up | B | 0% |
| 1 May 2026 | $6.0B | $2.9B – $8.5B | $6.0B (0%) | after a round | 199 | up | B | 0% |
| 1 Jun 2026 | $6.0B | $2.0B – $8.5B | $6.0B (0%) | after a round | 199 | flat | C | 0% |
| 1 Jul 2026 | $6.0B | $1.8B – $8.5B | $6.0B (0%) | after a round | 199 | flat | C | 0% |
| 1 Aug 2026 | $6.0B | $1.7B – $8.5B | $5.9B (-1%) | after a round | 195 | flat | C | 0% |
| 1 Sep 2026 | $6.0B | $1.6B – $8.5B | $5.9B (-1%) | after a round | 195 | flat | C | 0% |
| 1 Oct 2026 | $6.0B | $1.5B – $8.5B | $5.9B (-2%) | after a round | 198 | flat | C | 0% |
| 24 Oct 2026 | $6.0B | $1.5B – $8.5B | $4.0B (-34%) | after a round | 198 | flat | C | 0% |
Key facts about Formation Bio
- Founded
- 2013
- Headquarters
- New York, United States
- Employees
- about 198 +9% in a year
- Total raised
- $528M
- Funding rounds
- 2
- Last round
- Series D Jun 2024
Formation Bio was founded in 2013 by Benjamine Liu and Linhao Zhang.
Formation Bio funding history
Formation Bio has 2 funding rounds on record, from Sep 2021 to Jun 2024, $528M in total. None disclosed a valuation.
Series D 26 Jun 2024
Led by Andreessen Horowitz; with Sanofi, Sequoia Capital, Thrive Capital, Emerson Collective, SV Angel, FPV Ventures, Lachy Groom.
Sources: prnewswire.com, techcrunch.com, ddw-online.com and 2 more
$372M
Series C 30 Sep 2021
Led by Sam Altman, Lachy Groom; with Sequoia Capital, Thrive Capital, Casdin Capital, Dragoneer Investment Group, Section 32, Kleiner Perkins, Spark Capital, Felicis, Sound Ventures, Arrowmark.
Sources: finsmes.com, research.contrary.com
$156M
Formation Bio investors
17 investors have backed Formation Bio; Lachy Groom, Andreessen Horowitz and Sam Altman led at least one round.
- Lachy Groom lead, 2 rounds
- Andreessen Horowitz lead
- Sam Altman lead
- Sequoia Capital 2 rounds
- Thrive Capital 2 rounds
- Arrowmark
- Dragoneer Investment Group
- Emerson Collective
- Felicis
- Kleiner Perkins
- Sanofi
- Section 32
- Sound Ventures
- Spark Capital
- SV Angel
What Formation Bio does
Formation Bio works in pharmaceutical products, with 15 recorded offerings and customers in pharmaceuticals and biotechnology.
Formation Bio is a United States pharmaceutical company that develops and acquires clinical-stage drug assets, utilizing proprietary technology platforms to support drug development. The company operates a platform that integrates artificial intelligence and big data to enhance clinical trial design and data quality, and engages in in-licensing and out-licensing activities to expand access to new treatments. Formation Bio serves pharmaceutical and biotechnology partners and targets areas such as inflammation, autoimmune diseases, and chronic conditions.
Description from Veridion's company data.
Products and services
- AI-Driven Drug Development Solutions
- Clinical-Stage Asset Acquisition and Development
- Drug Candidate Pipeline Management
- Clinical Trial Design and Optimization
- Clinical Trial Data Quality Enhancement
- Drug Selection and Therapeutic Gap Analysis
- Proprietary Platform Development for Drug Development
- In-Licensing and Out-Licensing Services
- Accelerated Therapeutic Introduc tion Services
- Autoimmune Disease Therapeutic Development
- Inflammation Therapeutic Development
- Osteoarthritis Therapeutic Development
- Eczema Therapeutic Development
- Big Data Analytics in Drug Development
- Flexible Financing Pathway Analysis
Markets
- Pharmaceuticals
- Biotechnology
Technology
- AI-Native Drug Development Platforms
- Big Data Analytics for Drug Development
- AI-Driven Trial Design
- AI-Driven Trial Completion
Business model
- Business-to-Business
- Software-as-a-Service
- Licensing
Industry codes (NAICS)
- 541714 Research and Development in Biotechnology (except Nanobiotechnology) 100% match
Questions about Formation Bio
What is Formation Bio worth?
Valuation $6.0B (range $1.5B to $8.5B), as of 24 Oct 2026.
Has Formation Bio raised money?
Formation Bio has 2 funding rounds on record, from Sep 2021 to Jun 2024, $528M in total. None disclosed a valuation.
Who has invested in Formation Bio?
Lachy Groom, Andreessen Horowitz, Sam Altman, Sequoia Capital, Thrive Capital and Arrowmark, and 11 more. Lead investors include Lachy Groom, Andreessen Horowitz and Sam Altman.
How many people work at Formation Bio?
About 198, up 9% over the last year. Headcount grew from 170 in Mar 2024 to 198 in Sep 2026.
What does Formation Bio do?
Formation Bio works in pharmaceutical products, with 15 recorded offerings and customers in pharmaceuticals and biotechnology. Its main offerings are AI-Driven drug development solutions, clinical-stage asset acquisition and development and drug candidate pipeline management.
When was Formation Bio founded, and where is it based?
Formation Bio was founded in 2013 and is based in New York, United States. It has about 198 employees, up 9% over the last year.